Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance

Kaplan E., GÜNDÜZ U.

BIOMEDICINE & PHARMACOTHERAPY, vol.66, no.1, pp.29-35, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 66 Issue: 1
  • Publication Date: 2012
  • Doi Number: 10.1016/j.biopha.2011.09.002
  • Journal Name: BIOMEDICINE & PHARMACOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.29-35
  • Keywords: Breast cancer, Chemotherapy resistance, Etoposide, DNA MISMATCH REPAIR, STRAND BREAK REPAIR, TOPOISOMERASE-II, DRUG-RESISTANCE, HOMOLOGOUS RECOMBINATION, MULTIDRUG RESISTANCE, CANCER, LINES, MACHINERY, POISONS
  • Middle East Technical University Affiliated: Yes

Abstract

Purpose: Development of resistance against anti-cancer drugs is one of the major obstacles of chemotherapy in the treatment of cancer. Etoposide is a topoisomerase II alpha (TOP2A) inhibitor, which is used in the treatment of breast cancer. Alterations in the expression of drug targets or DNA repair genes are among the important resistance mechanisms against TOP2A inhibitors. In this study, expression changes in TOP2A gene and two important mismatch repair (MMR) genes MSH2 and MLH1 were examined in order to understand the relationship between differential expression of these genes and drug resistance against etoposide.